The diagnosis is primarily influenced by the enlarged uterus and specific localized tenderness in the uterus [1]. Fibroids are present in 20 to 30 percent of females, with a prevalence that often begins between the ages of 30 and 50. They appear to be particularly common among women of African-Caribbean descent.

Fibroids are sensitive to estrogen, which stimulates their growth during pregnancy due to elevated estrogen levels. When they exceed their blood supply, they may experience ‘red degeneration,’ leading to necrotic tissue within the fibroid, which causes severe localized pain. An ultrasound examination can confirm the presence of fibroids by revealing an encapsulated mass within the uterus, while degeneration is indicated by the detection of cystic areas within that mass on the ultrasound.

Typically, fibroids are found in women who are of reproductive age and tend to diminish during menopause [2]. These benign growths are the leading reason for surgical interventions among women in the United States. Around one-third of all hysterectomies performed are due to uterine fibroids. Nonetheless, most fibroids do not lead to significant issues and often do not require any medical intervention. Generally, they only become problematic when their position leads to heavy or irregular menstrual bleeding or challenges with reproduction. Additionally, large fibroids may exert pressure on adjacent pelvic organs, causing discomfort in the pelvis, increased urinary frequency, or constipation.

Causes

Fibroids are non-cancerous monoclonal tumors, each arising from the proliferation of a single smooth muscle cell [2]. The normal muscle cells (myocytes) become abnormal and are subsequently stimulated to develop into tumors. Factors such as genetic predisposition, hormonal influences, growth factors, and the formation of new blood vessels (angiogenesis) could all contribute to the development and expansion of uterine fibroids.

Fibroids can range in size from tiny, microscopic growths to those comparable to the size of a full-term pregnancy. They are responsive to hormones, particularly estrogen and progesterone, though this relationship is intricate. In women of childbearing age, different fibroids may grow and shrink at various rates within the same individual. During menopause, these tumors typically cease to grow and might shrink due to a natural decrease in the body's estrogen levels.

Uterine fibroids are categorized based on their position within the uterus. The standard classifications consist of submucosal (located under the endometrium), intramural (found within the muscular wall of the uterus), and subserosal (situated beneath the uterine serosa). The most frequently encountered type is intramural leiomyomas, while submucosal fibroids are often linked to severe or extended bleeding. Both submucosal and subserosal fibroids can develop into pedunculated forms. A parasitic leiomyoma refers to a pedunculated fibroid that connects to pelvic organs or omentum, and subsequently forms its own supply of blood.

Fibroids possess a significant amount of extracellular matrix, which includes fibronectin, collagen, and proteoglycan, and they are encased in a pseudocapsule composed of compressed areolar tissue along with smooth muscle cells. This pseudocapsule is characterized by a sparse quantity of both blood and lymphatic vessels. It is this pseudocapsule that differentiates fibroids from adenomyosis, which tends to be organized in a more diffuse manner within the myometrium. As leiomyomas grow larger, they may surpass their blood supply leading to infarction and degeneration, which can result in pain.

Risks

Uterine fibroids are frequently linked with African American ancestry, non-smokers, early onset of menstruation, women who have never given birth, perimenopausal status, higher alcohol consumption, and hypertension [2]. In general, low-dose oral contraceptive pills are thought to offer protection against the formation of new fibroids, though they may provoke growth in existing ones. An exception could be observed in females who begin taking OCPs between ages 13 and 16. The application of hormone replacement therapy in postmenopausal women diagnosed with fibroids is related to fibroid expansion, yet it often does not lead to noticeable clinical manifestations. The likelihood of developing fibroids diminishes with increasing parity, the use of oral contraceptives, and the use of injectable depot medroxyprogesterone acetate.

Symptoms

A majority of women with fibroids, ranging from 50% to 65%, do not exhibit any noticeable clinical symptoms [2]. Among those who do experience symptoms, irregular uterine bleeding is the most prevalent complaint. This is predominantly caused by submucosal fibroids exerting pressure on the endometrial cavity. Abnormal bleeding typically appears as periods that are heavier and last longer than usual, previously referred to as menorrhagia. Fibroids may also lead to spotting after sexual intercourse, bleeding between menstrual cycles, or heavy and inconsistent bleeding, previously termed menometrorrhagia. The blood loss resulting from fibroids can contribute to chronic iron deficiency anemia, dizziness, feelings of weakness, and fatigue.

In most cases, pelvic pain is not a common symptom unless there is a compromise in the blood vessels, which is most frequently seen with subserosal pedunculated fibroids. However, individuals might experience secondary menstrual pain, particularly when there is significant or prolonged bleeding. Symptoms related to pressure, such as pelvic discomfort, constipation, hydronephrosis, and venous stasis, can vary based on the quantity, size, and placement of leiomyomas. If a fibroid exerts pressure on surrounding structures, patients may report issues like constipation, frequent urination, or even urinary retention due to the increasing congestion in the pelvic space.

Submucosal fibroids can influence embryo implantation, the development of the placenta, and the continuation of pregnancy. The removal of submucosal fibroids in individuals experiencing infertility is associated with higher rates of successful conception. Intramural and subserosal fibroids generally do not have a significant impact on the chances of conception or the risk of miscarriage, unless there are numerous fibroids present. Nevertheless, most women who have fibroids can conceive without major obstacles. When fibroids are numerous, substantial in size (ranging from 5 to 10 cm), or positioned behind the placenta, they might lead to higher occurrences of early labor and delivery, abnormal fetal positioning, ineffective labor, and the need for cesarean sections. The rate of complications during the antepartum and intrapartum periods ranges from 10% to 40%.

Diagnosis

Fibroids can exist as either single or multiple formations and may be situated throughout the uterus, including subserosal, intramural, or submucosal areas, as well as the cervix and the broad ligament of the uterus [3]. While larger fibroids can sometimes be identified through a bimanual pelvic examination, the diagnosis predominantly occurs via a gynecological ultrasound. Magnetic resonance imaging may also be used for diagnosis, however, neither of these imaging techniques reliably differentiate fibroids from their infrequent malignant variants. The distinction becomes more challenging particularly when larger fibroids exhibit changes like infarction or bleeding.

Fibroids are non-cancerous tumors that arise from a single type of cell, with roughly half showing basic chromosomal abnormalities. The exact causes remain unclear, yet several elements contribute to the emergence and enlargement of fibroids, such as genetic susceptibility, growth factors, along with the influence and interaction of the hormones estrogen and progesterone. Recognized risk factors encompass obesity, diabetes, hypertension, being of African descent, and polycystic ovary syndrome.

Typically, fibroids tend to reduce in size after menopause due to the decline in estrogen levels. Accordingly, generally only symptomatic fibroids in women who are still able to conceive necessitate treatment. Treatment alternatives can be medicinal, which involves medications intended to decrease the size of fibroids or alleviate symptoms, or surgical interventions such as uterine artery embolization, myomectomy, or hysterectomy.

Every fibroid must undergo histological analysis to rule out any malignant transformations. Characteristically, fibroids display a white or cream whorled surface that can be easily separated from the surrounding myometrium. Under the microscope, they comprise uniform smooth muscle cells aligned in bundles, featuring elongated nuclei and thin cytoplasmic extensions. Notable nuclear atypia, necrosis, and active mitotic processes will inform pathologists that the fibroid could potentially be a leiomyosarcoma instead of a typical leiomyoma.

Degeneration

Degenerative pain generally begins gradually, and several women cope with minimal measures such as paracetamol and resting until the discomfort alleviates [1]. Nonetheless, the pain can often become intense enough to necessitate hospitalization for opioid pain relief. Opioids are considered safe during pregnancy if their usage is not prolonged. If a woman is unable to drink or is experiencing vomiting due to the pain, intravenous fluids may be necessary.

Most women remain in good overall health, but it is advisable to conduct a full blood count and check C-reactive protein levels to evaluate hemoglobin, white blood cell count, and inflammation indicators.

Degenerating fibroids typically do not adversely affect pregnancy, except in rare instances where sepsis develops, which can lead to miscarriage.

LMS

Leiomyosarcoma accounts for up to 80% of uterine sarcomas when carcinosarcomas are excluded [4]. This type of sarcoma commonly manifests in individuals aged 45 to 55 and originates from uterine smooth muscle without a prior association with uterine myomas, which is an uncommon development. When fibroids are diagnosed pre-operatively, there is a 0.7% chance that the final histopathological report will indicate leiomyosarcoma. A swift enlargement of the fibroid or the onset of pain should raise concerns regarding the potential development of leiomyosarcoma. The diagnostic accuracy of uterine curettage is only between 10% and 20%.

They are predominantly solitary with a fleshy look. Over 75% have dimensions that exceed 5. 0 cm. Identifiable areas showing necrosis, bleeding, or cystic features present diffuse mild to severe variations in cell structure. They may display a high mitotic index (values above 10 per 10 high power fields). Evidence of coagulative cell death within tumors can also be seen in patients (according to Stanford’s criteria). No grading framework exists for LMS as it does not relate to survival rates.

Contrast-enhanced MRI generally offers greater diagnostic precision (0. 94) compared to diffusion-weighted imaging (0. 52). The specificity scores are also superior (0. 96 against 0. 36) for distinguishing LMS/STUMP from fibroids. A contrast-enhanced CT scan for the chest and abdomen is applicable to evaluate the spread beyond the uterus.

Pregnant Women

Improving anemia before delivery is crucial for minimizing complications associated with postpartum hemorrhage and the necessity for blood transfusions [5]. Assessing symphysial fundal height is unreliable in women who have multiple or large fibroids (greater than 5 cm in diameter). It is recommended that these individuals undergo periodic growth scans starting at 28 weeks to detect babies with restricted intrauterine growth and to identify abnormal fetal presentations during the third trimester.

Monitoring through ultrasound scans can help in spotting fibroids that are growing quickly, allowing for early intervention in rare cases of malignancy. If there are challenges in defining the fibroids via ultrasound, an MRI can provide additional insights, distinguishing between atypical leiomyomas and uterine sarcomas. MRI is safe to perform during pregnancy. Abdominal discomfort in pregnant individuals with fibroids can stem from red degeneration, pressure effects, or torsion of pedunculated fibroids, particularly in the later trimesters. It is essential to rule out other sources of abdominal pain, such as preterm labor. Both physical examinations and ultrasound scans are beneficial for pregnant women with known fibroids who experience acute pain.

Using paracetamol and opioids such as morphine is considered safe during pregnancy. Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective for fibroid-related pain, but caution is necessary in the third trimester due to potential risks like early closure of the ductus arteriosus, which may contribute to fetal pulmonary hypertension. The presence of uterine fibroids does not preclude the option of external cephalic version (ECV) for women experiencing malpresentation, provided there are no significant cervical fibroids.

Antenatal myomectomy is infrequently needed for ongoing bleeding or intense pain due to a degenerating fibroid, particularly one that is growing rapidly or a torted pedunculated fibroid. This procedure is viewed as safer when conducted in the first and second trimesters. Research comparing outcomes in women with fibroids who had antepartum myomectomy versus those who did not indicated that such myomectomy is advantageous for improving reproductive and pregnancy outcomes when executed early in select cases. There was an increased rate of Caesarean sections among women who had the antepartum myomectomy, along with extended hospital stays after surgery; however, there was no heightened risk of peripartum hysterectomy. Antepartum myomectomy is not standard practice in the UK, thus, pregnant women needing this procedure should be referred to specialized centers that have experience in performing it.

Treatment

Most instances of uterine fibroids do not necessitate intervention, and monitoring without immediate action is suitable [2]. Nonetheless, the identification of leiomyoma must be clear-cut. It is essential to eliminate other possible pelvic masses, and patients with fibroids that are actively increasing in size should have follow-ups every six months to assess growth and size.

Treatment should be contemplated when leiomyomas lead to significant pain, abnormal bleeding patterns, infertility, or symptoms of pressure. If fibroids display signs of rapid growth post-menopause or show a significant increase, monitoring should commence, and treatment options should be explored. The selection of therapy is influenced by factors such as the patient's age, current pregnancy status, intentions for future pregnancies, as well as the fibroids' size and positioning.

There are various medical treatments available for the symptoms associated with leiomyomas. Nonhormonal treatments, which encompass nonsteroidal anti-inflammatory medications and antifibrinolytics (such as tranexamic acid), offer limited effectiveness in alleviating dysmenorrhea, heavy or prolonged menstrual bleeding, and anemia.

During pregnancy, fibroids are usually managed by observation but could potentially lead to complications like abnormal fetal positioning at delivery or obstructed labor if a fibroid is located in the pelvis [1]. In such situations, a cesarean delivery is recommended. Additionally, fibroids pose an independent risk for postpartum bleeding as they may hinder the uterus from contracting effectively after the placenta is delivered. Most fibroids tend to reduce in size naturally in the weeks following childbirth, so any surgical intervention should generally be postponed for a minimum of three months post-delivery.

Prevention

The strategies for preventing uterine fibroids can be categorized into three primary segments: (1) primary prevention-avoiding the occurrence of fibroids altogether; (2) secondary prevention-proactive and immediate management of fibroids once they arise; and (3) tertiary prevention-supporting women after they have undergone treatment for fibroids [6].

Primary Prevention - As the precise origin of fibroids remains unclear, it is challenging to suggest specific preventive measures for women aimed at avoiding fibroids. Nonetheless, emphasis should be placed on nutrition and healthy lifestyles, while long-term use of combined oral contraceptives has been found to lower the risk of fibroid development.

Furthermore, since fibroids generally form in older women experiencing infertility, it might be beneficial to advise women to consider completing their families at younger ages to minimize the risks and effects associated with fibroids.

Secondary Prevention - This largely relies on the timely identification and treatment of fibroids. A significant challenge in many developing nations is that women frequently wait too long to seek help for fibroids and their related complications. Clinical observations reveal that many women pursue treatment only after having lived with fibroids for numerous years, often facing irreversible harm and serious complications. This delay may stem from cultural beliefs, religious factors, overwhelming fears of surgical procedures, or financial constraints. As a result, initiatives should be implemented to inform women about fibroids, their prevention, and treatment modalities to encourage earlier access to healthcare for fibroid concerns.

Physicians in less developed nations also require training in utilizing different methods for early management of fibroids, particularly those that incorporate minor surgical procedures alongside conservative medical and surgical options. These techniques will boost the chances of women accepting initial treatment for their fibroids.

Tertiary Prevention - For women undergoing hysterectomy, post-surgery care and counseling can help them handle the psychological and sexual implications of having their uterus removed. This is especially true for relatively younger individuals whose ovaries have also been taken out. Hormone replacement therapy may be beneficial for these women to manage the associated changes.

For younger females who have had myomectomy or other less invasive treatments, the main focus should be on their future ability to conceive. Research shows that individuals can become pregnant within a few months post-myomectomy. Therefore, they should be encouraged to attempt pregnancy as soon as they have healed. Indeed, our observations suggest that such pregnancies can reduce the likelihood of these women developing new fibroids.

For those who underwent myomectomy in the context of significant tubal illness or other severe infertility issues, it is advisable to recommend treatment through assisted reproductive technologies. When other methods do not yield results, women and couples should be guided to either accept their infertility or consider adopting a child.

Even though the term tumor may seem alarming, uterine fibroids are actually benign rather than cancerous. Fibroids are noncancerous growths that develop within or on the uterus. Nevertheless, they can lead to uncomfortable symptoms, such as heavy or painful menstrual cycles, a sense of fullness in the abdomen, frequent urges to urinate, discomfort during intercourse, and lower back pain. Many individuals with fibroids remain unaware of their presence because most do not exhibit any symptoms, with the growths simply existing in the body. As fibroids often do not cause any symptoms, they are frequently discovered accidentally during standard gynecological check-ups.

1. Bottomley C, MacSwan R, Rymer J. 100 Cases in Obstetrics and Gynaecology, Third Edition. CRC Press. Taylor and Francis Group. USA. 2025; 138.
2. Callahan TL, Caughey AB. Blueprints Obstetrics and Gynecology, Seventh Edition. Wolters Kluwer. USA. 2018; 231-237.
3. Shamil E, Ravi P, Chandra A. 100 Cases in Clinical Pathology and Laboratory Medicin, Second Edition. CRC Press. Taylor and Francis Group. USA. 2023; 140.
4. Aparajita, Ramchandra P, Barmon D, Kataki AC. Fundamentals in Gynaecologic Malignancy. Springer Nature Singapore. Singapore. 2022; 280-281.
5. Clark TJ, Antoun L. Fibroids in Pregnancy in Jha S. Madhuvrata, P. Gynaecology for the Obstetrician. Cambridge University Press. Cambridge. 2023; 17.
6. Okonofua F. Uterine Fibroid and Hysterectomy in Okonofua F, Balogun JA, Odunsi K, Chilaka VN. Contemporary Obstetrics and Gynecology for Developing Countries. Second Edition. Springer Nature Switzerland AG. Cham, Switzerland. 2021; 458.